DMPK Insights

DMPK Insights #16: HR-LC/MS: A Key Consideration for Environmental Fate and Plant/Livestock Metabolism Studies

For a captioned and video version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowl

DMPK Insights #15: Pharmacokinetics-Pharmacodynamics: Driving decision making with PKPD throughout Drug Discovery

For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-cente

DMPK Insights #14: Evolution of CNS Drug Disposition Models

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-14-cns-modelling/ In this podcast, Scott Summ

DMPK Insights #13: The Influence of QSAR and Physicochemical Descriptors on Drug Design​: A Brief History and New Paradigms​

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-13-qsar-physicochemical-descriptors/ In this

DMPK Insights #12: New Frontiers in Understanding the BBB Transport of Small Molecule Drugs

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-12-bbb-transporters/ In this podcast, Elena a

DMPK Insights #11: Drug Meets Bug: How the Gut Microbiome Shapes DMPK

For a captioned version or to access the transcript, please visit https://www.pharmaron.com/knowledge-center/dmpk-podcast-11-gut-microbiome/. In this podcast, Chris Bode

DMPK Insights #10: The DMPK Project Representative: An essential role of contribution, integration and evolution

In this podcast Simon Taylor (Pharmaron UK) interviews Kevin Beaumont, a highly experienced DMPK scientist, leader and drug developer who has lived and breathed the role

DMPK Insights #9: 60 and Beyond: Navigating the Frontiers of PBPK and QSP

In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th bi

DMPK Insights #8: It’s “All-go” with Oligos: Challenges and Opportunities in LC-MS of Therapeutic

In this podcast, Robert MacNeill, Professor Michael Bartlett of the University of Georgia and Dr. Guilherme Guimaraes of Biogen, will focus on oligonucleotide LC-MS cover

DMPK Insights #7: Carboxylic Acids and DILI – Conjugation and Reputation

In this podcast, Professor Ian Wilson, a globally recognised and leading expert in drug metabolism, with over 500 publications in the field, takes us on an engaging journ

DMPK Insights #6: Protein Mass Spectrometry: Advancing the Bioanalysis of Biotherapeutics and Biomarkers

In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics. The episode explores the following: The

DMPK Insights #4: DMPK Past, Present and Future – A Festive Tale

This podcast format is inspired by the Charles Dicken’s novella “A Christmas Carol” whereby Phil Jeffrey (Bicycle Therapeutics), Beth Williamson (UCB) and Daniel Price (N

DMPK Insights #5: Mass Spectrometry Imaging - Past, Present and Future

In this podcast, Josephine Bunch, Principal Research Scientist and Co-Director of the National Centre of Excellence in Mass Spectrometry (NiCE-MSI) at NPL,  talks about h

DMPK Insights #3: Free Drug Theory: No Longer Just a Hypothesis?

In this podcast, Scott Summerfield, Senior Director, Pharmaceutical Metabolism at Pharmaron discusses his recent publication on Free Drug Theory (FDT) with Simon includin

DMPK Insights #2: Pathways to Successful Drug Design – Discovery Metabolite ID

In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery

DMPK Insights #1: Candidate Survival – 3 Pillars to 5Rs and Beyond

In this podcast, Dr. Paul Morgan, Head of DMPK at Grünenthal Group, discusses the development of the publication that introduced the “5R framework” and improved the likel